Advertisement
Table 1 General characteristics of study participants at baseline study
| Placebo group (n = 30) | Probiotic group (n = 30) | P 1 | |
|---|---|---|---|
| Age (year) | 61.8 ± 9.8 | 60.7 ± 9.4 | 0.64 |
| Familial history (%) | 10 (33.7) | 11 (36.7) | 0.78† |
| Height (cm) | 163.2 ± 7.1 | 162.5 ± 7.2 | 0.72 |
| Weight at study baseline (kg) | 78.2 ± 11.8 | 80.2 ± 15.3 | 0.57 |
| Weight at end-of-trial (kg) | 78.2 ± 12.0 | 80.2 ± 15.3 | 0.56 |
| Weight change (kg) | − 0.03 ± 1.1 | 0.04 ± 1.0 | 0.78 |
| BMI at study baseline (kg/m2) | 29.3 ± 4.1 | 30.3 ± 5.2 | 0.42 |
| BMI at end-of-trial (kg/m2) | 29.3 ± 4.1 | 30.3 ± 5.2 | 0.41 |
| BMI change (kg/m2) | − 0.01 ± 0.4 | 0.06 ± 0.4 | 0.81 |
| Smoking (%) | 3 (10.0) | 3 (10.0) | 1.00† |
| Aspirin 80 mg (%) | 30 (100) | 30 (100) | 1.00† |
| Statin (%) | 30 (100) | 30 (100) | 1.00† |
| Insulin therapy (%) | 8 (26.7) | 7 (23.3) | 0.76† |
| Antidiabetic drugs (%) | |||
| Monotherpy | 16 (72.7) | 17 (70.8) | |
| Combination therapy | 6 (27.3) | 7 (29.2) | 0.88† |
| Hypertension (%) | 22 (73.3) | 23 (76.7) | 0.76† |
| ACEI/ARB drugs (%) | 30 (100) | 30 (100) | 1.00† |
| Blocker drugs (%) | |||
| β-blocker | 28 (93.3) | 29 (96.7) | |
| Calcium channel blocker | 2 (6.7) | 1 (3.3) | 0.55† |
| Duration of DM (year) | 6.8 ± 2.2 | 6.6 ± 1.9 | 0.61 |
| Duration of CHD (year) | 9.5 ± 2.2 | 9.3 ± 1.6 | 0.78 |
